Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms
出版年份 2017 全文链接
标题
Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 18, Issue 11, Pages 2420
出版商
MDPI AG
发表日期
2017-11-16
DOI
10.3390/ijms18112420
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer
- (2018) Suresh S. Ramalingam et al. JOURNAL OF CLINICAL ONCOLOGY
- Prospect of rindopepimut in the treatment of glioblastoma
- (2017) Aladine A. Elsamadicy et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas
- (2017) June-Koo Lee et al. JOURNAL OF CLINICAL ONCOLOGY
- A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R
- (2017) E-E Ke et al. Journal of Thoracic Oncology
- Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
- (2017) Michael Weller et al. LANCET ONCOLOGY
- Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation
- (2017) Toshimitsu Yamaoka et al. MOLECULAR CANCER RESEARCH
- The EMT spectrum and therapeutic opportunities
- (2017) Dominic C. Voon et al. Molecular Oncology
- Targeted therapies for gastric cancer: failures and hopes from clinical trials
- (2017) Maria Apicella et al. Oncotarget
- Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy
- (2016) Yoshihisa Kobayashi et al. CANCER SCIENCE
- 190TiP: ELUXA 1: Phase II study of BI 1482694 (HM61713) in patients (pts) with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI)
- (2016) K. Park et al. Journal of Thoracic Oncology
- Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer
- (2016) Chee-Seng Tan et al. LUNG CANCER
- Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab
- (2016) M. Iida et al. MOLECULAR CANCER THERAPEUTICS
- Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI–Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation
- (2016) Toshimitsu Yamaoka et al. MOLECULAR CANCER THERAPEUTICS
- The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies
- (2015) M. J. Niederst et al. CLINICAL CANCER RESEARCH
- Ultra-Sensitive Detection of the Pretreatment EGFR T790M Mutation in Non-Small Cell Lung Cancer Patients with an EGFR-Activating Mutation Using Droplet Digital PCR
- (2015) M. Watanabe et al. CLINICAL CANCER RESEARCH
- Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Giorgio Scagliotti et al. JOURNAL OF CLINICAL ONCOLOGY
- Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin
- (2015) Matthew G Oser et al. LANCET ONCOLOGY
- The genomic landscape of response to EGFR blockade in colorectal cancer
- (2015) Andrea Bertotti et al. NATURE
- AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
- (2015) Pasi A. Jänne et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer
- (2015) M. Russo et al. Cancer Discovery
- The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer
- (2015) Kimio Yonesaka et al. Oncotarget
- TheBimdeletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non-small cell lung cancer
- (2014) Mingchuan Zhao et al. CANCER
- ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
- (2014) Carlos L. Arteaga et al. CANCER CELL
- AXL Mediates Resistance to Cetuximab Therapy
- (2014) T. M. Brand et al. CANCER RESEARCH
- HER2 aberrations in cancer: Implications for therapy
- (2014) Min Yan et al. CANCER TREATMENT REVIEWS
- Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer
- (2014) E. Van Cutsem et al. CLINICAL CANCER RESEARCH
- The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR-Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial
- (2014) C. Costa et al. CLINICAL CANCER RESEARCH
- TGF and Amphiregulin Paracrine Network Promotes Resistance to EGFR Blockade in Colorectal Cancer Cells
- (2014) S. Hobor et al. CLINICAL CANCER RESEARCH
- Overexpression of NRG1 promotes progression of gastric cancer by regulating the self-renewal of cancer stem cells
- (2014) Myoung-Eun Han et al. JOURNAL OF GASTROENTEROLOGY
- Clinical Significance of BIM Deletion Polymorphism in Non–Small-Cell Lung Cancer with Epidermal Growth Factor Receptor Mutation
- (2014) Kazutoshi Isobe et al. Journal of Thoracic Oncology
- Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
- (2014) Yi-Long Wu et al. LANCET ONCOLOGY
- Targeted molecular therapies against epidermal growth factor receptor: Past experiences and challenges
- (2014) D. A. Reardon et al. NEURO-ONCOLOGY
- AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
- (2014) D. A. E. Cross et al. Cancer Discovery
- Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor-Resistant EGFR-Mutant Lung Cancer with and without T790M Mutations
- (2014) Y. Y. Janjigian et al. Cancer Discovery
- Oncogenic ERBB3 Mutations in Human Cancers
- (2013) Bijay S. Jaiswal et al. CANCER CELL
- Erlotinib Resistance in Lung Cancer Cells Mediated by Integrin 1/Src/Akt-Driven Bypass Signaling
- (2013) R. Kanda et al. CANCER RESEARCH
- Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
- (2013) H. A. Yu et al. CLINICAL CANCER RESEARCH
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations
- (2013) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical and Biomarker Outcomes of the Phase II Vandetanib Study from the BATTLE Trial
- (2013) Anne S. Tsao et al. Journal of Thoracic Oncology
- Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition
- (2013) Barbara Burtness et al. LANCET ONCOLOGY
- Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer
- (2013) Anne M. Traynor et al. LUNG CANCER
- Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
- (2013) Jean-Yves Douillard et al. NEW ENGLAND JOURNAL OF MEDICINE
- EGFR Gene Copy Number as a Prognostic Marker in Colorectal Cancer Patients Treated with Cetuximab or Panitumumab: A Systematic Review and Meta Analysis
- (2013) Zheng Jiang et al. PLoS One
- Nuclear EGFR as a molecular target in cancer
- (2013) Toni M. Brand et al. RADIOTHERAPY AND ONCOLOGY
- Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer
- (2013) H. Yasuda et al. Science Translational Medicine
- Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer
- (2013) Chao He WORLD JOURNAL OF GASTROENTEROLOGY
- Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 (HER2) Tyrosine Kinase Mutations in Lung Adenocarcinomas
- (2012) M. E. Arcila et al. CLINICAL CANCER RESEARCH
- Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab
- (2012) SHASHA LV et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Dual Targeting of the Epidermal Growth Factor Receptor Using the Combination of Cetuximab and Erlotinib: Preclinical Evaluation and Results of the Phase II DUX Study in Chemotherapy-Refractory, Advanced Colorectal Cancer
- (2012) Andrew J. Weickhardt et al. JOURNAL OF CLINICAL ONCOLOGY
- Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
- (2012) Vincent A Miller et al. LANCET ONCOLOGY
- Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
- (2012) Sandra Misale et al. NATURE
- Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
- (2012) Zhenfeng Zhang et al. NATURE GENETICS
- Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer
- (2012) Clara Montagut et al. NATURE MEDICINE
- A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer
- (2012) King Pan Ng et al. NATURE MEDICINE
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Overcoming resistance to EGFR inhibitor in head and neck cancer: A review of the literature
- (2012) Guilherme Rabinowits et al. ORAL ONCOLOGY
- Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1
- (2012) K. Ohashi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR -Mutant Lung Cancers That Lack the Second-Site EGFR T790M Mutation
- (2012) Ken Takezawa et al. Cancer Discovery
- Neuregulin-1-Mediated Autocrine Signaling Underlies Sensitivity to HER2 Kinase Inhibitors in a Subset of Human Cancers
- (2011) Timothy R. Wilson et al. CANCER CELL
- HB-EGF and PDGF Mediate Reciprocal Interactions of Carcinoma Cells with Cancer-Associated Fibroblasts to Support Progression of Uterine Cervical Cancers
- (2011) T. Murata et al. CANCER RESEARCH
- Anti-EGFR-targeting agents in recurrent or metastatic head and neck carcinoma: A meta-analysis
- (2011) Fausto Petrelli et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Cetuximab and panitumumab in KRAS wild-type colorectal cancer: a meta-analysis
- (2011) Fausto Petrelli et al. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
- Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non–Small-Cell Lung Cancer
- (2011) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Hepatocyte Growth Factor Expression in EGFR Mutant Lung Cancer with Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors in a Japanese Cohort
- (2011) Seiji Yano et al. Journal of Thoracic Oncology
- Phosphoinositide-3-Kinase Catalytic Alpha and KRAS Mutations are Important Predictors of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-small Cell Lung Cancer
- (2011) Vienna Ludovini et al. Journal of Thoracic Oncology
- Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma
- (2011) Hidetaka Uramoto et al. LUNG CANCER
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
- (2011) L. V. Sequist et al. Science Translational Medicine
- BIM Expression in Treatment-Naive Cancers Predicts Responsiveness to Kinase Inhibitors
- (2011) A. C. Faber et al. Cancer Discovery
- Epidermal Growth Factor Receptor cooperates with Src Family Kinases in acquired resistance to cetuximab
- (2010) Deric L. Wheeler et al. CANCER BIOLOGY & THERAPY
- Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC
- (2010) Alexa B. Turke et al. CANCER CELL
- Loss of PTEN Expression by Blocking Nuclear Translocation of EGR1 in Gefitinib-Resistant Lung Cancer Cells Harboring Epidermal Growth Factor Receptor-Activating Mutations
- (2010) C. Yamamoto et al. CANCER RESEARCH
- A Phase II study of anti–epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme
- (2010) Linna Li et al. JOURNAL OF NEUROSURGERY
- Comparison of the Incidence and Pattern of Interstitial Lung Disease During Erlotinib and Gefitinib Treatment in Japanese Patients with Non-small Cell Lung Cancer: The Okayama Lung Cancer Study Group Experience
- (2010) Katsuyuki Hotta et al. Journal of Thoracic Oncology
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Cyclooxygenase-2 Is a Novel Transcriptional Target of the Nuclear EGFR-STAT3 and EGFRvIII-STAT3 Signaling Axes
- (2010) H.-W. Lo et al. MOLECULAR CANCER RESEARCH
- Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer
- (2010) K Vuoriluoto et al. ONCOGENE
- Rapidly Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in NSCLC Cell Lines through De-Repression of FGFR2 and FGFR3 Expression
- (2010) Kathryn E. Ware et al. PLoS One
- ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation
- (2010) Fumin Shi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening
- (2009) Piyush B. Gupta et al. CELL
- Nuclear Translocation of the Epidermal Growth Factor Receptor Family Membrane Tyrosine Kinase Receptors
- (2009) S.-C. Wang et al. CLINICAL CANCER RESEARCH
- Nuclear EGFR contributes to acquired resistance to cetuximab
- (2009) C Li et al. ONCOGENE
- Skin toxicities associated with epidermal growth factor receptor inhibitors
- (2009) Tianhong Li et al. Targeted Oncology
- MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients
- (2008) F. Cappuzzo et al. ANNALS OF ONCOLOGY
- Epithelial-to-Mesenchymal Transition and Integrin-Linked Kinase Mediate Sensitivity to Epidermal Growth Factor Receptor Inhibition in Human Hepatoma Cells
- (2008) B. C. Fuchs et al. CANCER RESEARCH
- PIK3CA Mutations and Copy Number Gains in Human Lung Cancers
- (2008) H. Yamamoto et al. CANCER RESEARCH
- EXEL-7647 Inhibits Mutant Forms of ErbB2 Associated with Lapatinib Resistance and Neoplastic Transformation
- (2008) T. Trowe et al. CLINICAL CANCER RESEARCH
- Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
- (2008) Rafael G. Amado et al. JOURNAL OF CLINICAL ONCOLOGY
- Real-time quantitative polymerase chain reaction (qPCR) analysis with fluorescence resonance energy transfer (FRET) probes reveals differential expression of the fourERBB4juxtamembrane region variants between medulloblastoma and pilocytic astrocytoma
- (2008) N. Zeng et al. NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY
- EGFR Antagonists in Cancer Treatment
- (2008) Fortunato Ciardiello et al. NEW ENGLAND JOURNAL OF MEDICINE
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- (2008) Christos S. Karapetis et al. NEW ENGLAND JOURNAL OF MEDICINE
- The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
- (2008) C.-H. Yun et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started